Home
2021/22 Media Kit
Continued Medical Education
Cancer A – Z
Drug Developmemt Technologies
A Novel Technology based on Somatic Hypermutation (SHM)
Editorial Advisory Board
Join Our Editorial Advisory Board
Contact Us
Terms and Conditions
Publications
ADC Review | J. Antibody-drug Conjugates
Resources for For Clinicians
Drug Map (ADC)
Peer Review Articles
The Review
Changing Strategies in the War on Cancer
Changing Strategies in the War on Cancer – Episode 1
Changing Strategies in the War on Cancer – Episode 2
Changing Strategies in the War on Cancer – Episode 3
Centers of the Cancer Universe: A Half-Century of Progress Against Cancer
Journal of CAR T-Cell Therapy
About CAR T-cells
Frequently Asked Questions
Types of Articles
Submit a Manuscript
The Onco’Zine Brief
The Network
The Episodes
How to Support The Onco’Zine Brief
Corporate Underwriting and Sponsorship
The Onco’Zine Dossier
Thalidomide: A History
Thalidomide: In the Shadow of Death
Controversy: The involvement of Ciba AG in the development of Thalidomide
Thalidomide’s Secret Past: The Link with Nazi Germany
Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer
Smoking and Health
New Surgeon General’s Report Presents the Unfiltered Truth About Tobacco
Smoking and the Lost Legacy of the First Surgeon General’s Report on Smoking and Health
Tobacco Control in the United States Has Saved 8 Million Lives In Last 50 Years
Tobacco Companies are Finally Moving Closer to Revealing the Truth about Smoking
The Harmful Effects of Smoking: The Public Denial in the Early-mid 1960s
Drug Approvals 2017 – 2020
Oncology & Hematology – FDA Drug Approvals 2018
Oncology & Hematology – FDA Drug Approvals 2019
Oncology & Hematology – FDA Drug Approvals 2020
Articles
Latest Articles
Expert Interviews
Editorials and Commentaries
Eric Rosenthal Reports
Publications
News
Business & Economics
Clinical Development
Conference Coverage
The Onco’Zine Brief
The Episodes
National Advertising
Agenda
Directory
Join Today
Event Agenda
Video
Careers
Search
About
Advertise
Advisory Board
Contact Us
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Onco'Zine
Advertisement #1
Home
2021/22 Media Kit
Continued Medical Education
Cancer A – Z
Drug Developmemt Technologies
A Novel Technology based on Somatic Hypermutation (SHM)
Editorial Advisory Board
Join Our Editorial Advisory Board
Contact Us
Terms and Conditions
Publications
ADC Review | J. Antibody-drug Conjugates
Resources for For Clinicians
Drug Map (ADC)
Peer Review Articles
The Review
Changing Strategies in the War on Cancer
Changing Strategies in the War on Cancer – Episode 1
Changing Strategies in the War on Cancer – Episode 2
Changing Strategies in the War on Cancer – Episode 3
Centers of the Cancer Universe: A Half-Century of Progress Against Cancer
Journal of CAR T-Cell Therapy
About CAR T-cells
Frequently Asked Questions
Types of Articles
Submit a Manuscript
The Onco’Zine Brief
The Network
The Episodes
How to Support The Onco’Zine Brief
Corporate Underwriting and Sponsorship
The Onco’Zine Dossier
Thalidomide: A History
Thalidomide: In the Shadow of Death
Controversy: The involvement of Ciba AG in the development of Thalidomide
Thalidomide’s Secret Past: The Link with Nazi Germany
Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer
Smoking and Health
New Surgeon General’s Report Presents the Unfiltered Truth About Tobacco
Smoking and the Lost Legacy of the First Surgeon General’s Report on Smoking and Health
Tobacco Control in the United States Has Saved 8 Million Lives In Last 50 Years
Tobacco Companies are Finally Moving Closer to Revealing the Truth about Smoking
The Harmful Effects of Smoking: The Public Denial in the Early-mid 1960s
Drug Approvals 2017 – 2020
Oncology & Hematology – FDA Drug Approvals 2018
Oncology & Hematology – FDA Drug Approvals 2019
Oncology & Hematology – FDA Drug Approvals 2020
Articles
Latest Articles
Expert Interviews
Editorials and Commentaries
Eric Rosenthal Reports
Publications
News
Business & Economics
Clinical Development
Conference Coverage
The Onco’Zine Brief
The Episodes
National Advertising
Agenda
Directory
Join Today
Event Agenda
Video
Careers
Home
Tags
TNBC
Tag: TNBC
Scientists Identify a Molecular Biomarker for Cancer that Ventures Off to...
Editorial Team
-
August 8, 2022
Benefits of Pre-surgical Immunotherapy Independent of Race in Aggressive Breast Cancer
Editorial Team
-
July 29, 2022
ASCO 2022: Exploring Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer
Danielle Garcia
-
June 4, 2022
Study Shows Molecular Mechanisms that may Cause Racial Disparity in TNBC
Editorial Team
-
March 15, 2022
Pembrolizumab Shows Significantly Prolonged Event-free Survival in High-Risk Early-Stage TNBC
Editorial Team
-
February 9, 2022
AmunBio and NorthShore University to Advance Cancer Immunotherapy with Engineered Oncolytic...
Peter Hofland, Ph.D
-
April 13, 2021
Novel Cancer Vaccine Combines Chemo + Immunotherapy to Treat Triple-negative Breast...
Lindsay Brownell
-
November 10, 2020
ESMO 2020: Encouraging Early-Stage Clinical Results with Sacituzumab Govitecan in Brain...
Editorial Team
-
September 18, 2020
Risk of Recurrence of Triple-Negative Breast Cancer May be Predicted by...
Peter Hofland, Ph.D
-
April 24, 2020
Sacituzumab Govitecan Approved in Metastatic Triple-negative Breast Cancer
Peter Hofland, Ph.D
-
April 22, 2020
1
2
Page 1 of 2
LATEST NEWS
Right to Know: The Critical Importance of Options and Choices in Skin Cancer Treatment
Alpesh Desai D.O.
-
August 11, 2022
Using Bayesian Designs to Inform Dose Recommendations in Clinical Trials
Edward Matthews
-
August 10, 2022
Mount Sinai Researchers Awarded Grant to Explore Therapeutic Approach to KRAS-Mutant Lung Tumors
Editorial Team
-
August 9, 2022
Osimertinib + Savolitinib Demonstrated 49% ORR in Lung Cancer Patients with MET Over-expression
Editorial Team
-
August 9, 2022
Tarlatamab Shows Encouraging Anti-tumor Activity Against SCLC in Phase 1 Trial
Editorial Team
-
August 9, 2022
X